Empire Resources Inc. ERS
7.00 0.00 (+0.00%)
At closeJun 28, 2019, 6:07 PM EDT
6.98 Day range 7.00
0.26 52-week range 7.47
- Market cap
- 57.75M
- P/E ratio
- 23.81
- Volume
- 16.30K
- Avg volume
- 24.16K
- Open
- 6.98
- Previous close
- 7.00
- Day's range
- 6.98 – 7.00
- 52-week range
- 0.26 – 7.47
- Earnings date
- Mar 31, 2017
No chart data for this range yet.
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 2.81
- 200-day average
- 5.19
Next earnings
Mar 31, 2017
Expected Mar 31, 2017. Consensus EPS estimate 0.00.
Financials — quick view
ERS Revenue — quarterly 100.63M
ERS Net income — quarterly 302.00K
ERS EPS — quarterly 0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 31, 2017 | Dec 1, 2016 | 0.00 | — | — | — |
| Nov 14, 2016 | Sep 1, 2016 | 0.00 | — | — | — |
| Aug 15, 2016 | Jun 1, 2016 | 0.00 | — | — | — |
| May 16, 2016 | Mar 1, 2016 | 0.00 | — | — | — |
| Mar 30, 2016 | Dec 1, 2015 | 0.00 | — | — | — |
News
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026 
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress 
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society ( 
Ex-Dividends For July 2, 2014
Your note
Sign in to keep a note on ERS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KAHN NATHAN | Officer | Disposition (Non Open Market) | May 3, 2017 | 0 |
| KAHN SANDRA | Officer | Disposition (Non Open Market) | May 3, 2017 | 0 |
| SMITH MORRIS J | Director | Disposition (Non Open Market) | May 3, 2017 | 0 |
| WRUBEL HARVEY | Director | Disposition (Non Open Market) | May 3, 2017 | 0 |